Giant Cell Arteritis Market

Market Overview:

The 7 major giant cell arteritis markets reached a value of US$ 1,130.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,825.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.45% during ​2024-2034​.

The giant cell arteritis market has been comprehensively analyzed in IMARC's new report titled "Giant Cell Arteritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Giant cell arteritis, also known as temporal arteritis, refers to a type of systemic vasculitis that affects medium- to large-sized arteries, most commonly the temporal arteries that run along the sides of the head. The ailment causes inflammation and damage to the walls of the arteries, leading to narrowing or blockage of blood flow. The symptoms can vary widely but generally include severe headaches, scalp tenderness, jaw pain when chewing, fatigue, fever, weight loss, muscle aches, etc. In some cases, the disease can cause permanent vision loss due to damage to the ophthalmic artery, which supplies blood to the optic nerve. The diagnosis of the condition typically involves a combination of clinical evaluation, blood tests, and imaging procedures. A doctor will often start by taking a detailed medical history and performing a physical exam, looking for signs of inflammation, such as tenderness over the temporal arteries. Several blood tests are used to measure markers of inflammation, including erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Additionally, an ultrasound or angiography may be performed to assess the affected arteries and check for signs of blockages.

The rising prevalence of autoimmune disorders, in which the body's immune system targets healthy tissues and causes inflammation in the blood vessels, is primarily driving the giant cell arteritis market. In addition to this, the increasing incidence of several potential risk factors, including respiratory infections, advancing age, inflammatory diseases like polymyalgia rheumatica, etc., is also bolstering the market growth. Furthermore, the widespread adoption of low-dose aspirin in combination with immunosuppressive drugs for reducing the likelihood of blood clot formation and other complications in patients is acting as another significant growth-inducing factor. Besides this, the emerging popularity of biologic therapies, such as tocilizumab, anakinra, abatacept, etc., to target specific components of the immune system involved in the inflammatory process is further creating a positive outlook for the market. Additionally, the escalating utilization of corticosteroid-sparing strategies on account of their several associated benefits, including minimal side effects, enhanced disease control, and a reduced risk of relapse, is also propelling the market growth. Moreover, the introduction of novel image-guided biopsies, such as ultrasound-guided temporal artery biopsy, which has improved the accuracy of diagnosis and lowered the need for invasive surgical biopsy procedures, is expected to drive the giant cell arteritis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the giant cell arteritis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for giant cell arteritis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the giant cell arteritis market in any manner.

Recent Developments:

• In April 2024, AbbVie announced positive top-line outcomes from SELECT-GCA, a Phase 3 multicenter, randomized, double-blind, placebo-controlled study, demonstrating that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen accomplished its primary endpoint of sustained remission from week 12 to week 52 in adults with giant cell arteritis.

Key Highlights:

• The average estimate ranges between 2.3/100,000 instances per year in the sixth decade of life to 44.7 per 100,000 instances per year in people in their ninth decade.
• The incidence is minimal in patients under the age of 50, but increases with age, with a median age of 75.
• The average presenting age is 72.5 years for women and 70.3 years for males.
• Women are affected 2–6 times more frequently than men.
• White patients of northern European heritage had the greatest incidence (30⁄100,000 in Norway) with giant cell arteritis, whereas African, Asian, and Arab groups had the lowest rates (1.47⁄100,000 in Japan).

Drugs:

Actemra is a first-in-class anti-IL-6 receptor (aIL-6R) treatment. IL-6 is thought to be important in initiating the inflammatory pathway, which adds to the symptoms of various inflammatory autoimmune diseases. Actemra binds to IL-6 receptors and inhibits the pro-inflammatory effects of IL-6 cytokines.

Guselkumab is a humanized monoclonal antibody, developed by Janssen Biotech for the treatment of giant cell arteritis. The drug is delivered by the intravenous and subcutaneous methods.

Upadacitinib (RINVOQ) is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases by AbbVie. Based on enzymatic and cellular assays, upadacitinib demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2. This drug is being studied in Phase 3 clinical trials for giant cell arteritis.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the giant cell arteritis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the giant cell arteritis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current giant cell arteritis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the giant cell arteritis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the giant cell arteritis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the giant cell arteritis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of giant cell arteritis across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of giant cell arteritis by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of giant cell arteritis by gender across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with giant cell arteritis across the seven major markets?
• What is the size of the giant cell arteritis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of giant cell arteritis?
• What will be the growth rate of patients across the seven major markets?
   

Giant Cell Arteritis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for giant cell arteritis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the giant cell arteritis market?
• What are the key regulatory events related to the giant cell arteritis market?
• What is the structure of clinical trial landscape by status related to the giant cell arteritis market?
• What is the structure of clinical trial landscape by phase related to the giant cell arteritis market?
• What is the structure of clinical trial landscape by route of administration related to the giant cell arteritis market?